World’s biggest multibillionaire investor is buying THIS by the ton [picture]

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

William Lis Biography and Net Worth

Director of Zai Lab

William Lis has been our Independent Director since October 2018. He has 28 years of biopharmaceutical experience. He is the Executive Chairman, and interim CEO of Jasper Therapeutics, Inc. where he led the company's 2019 Series A financing. Previously, Mr. Lis served as Chief Executive Officer and a Director of Portola Pharmaceuticals, Inc. from 2009 until 2018 after serving as Chief Operating Officer. Under his leadership, Portola successfully grew from a discovery-stage company to a fully integrated R&D and commercial organization, and independently discovered and developed Andexxa® and Bevyxxa® through commercial launch, and advanced cerdulatinib into clinical development. He led corporate partnerships and private and public financings including an initial public offering in 2013. The company grew into a multi-billion valuation company during his tenure.

Mr. Lis held executive positions at Scios, Inc. (a Johnson & Johnson company) where he last served as Sr. Vice President of Business Development and New Product Development, having led efforts for the in-licensing, development and pre-commercial launch for Xarelto®; He also held positions of increasing responsibility at Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) and Rhone Poulenc Rorer in sales, marketing, medical affairs and business development. He was involved in the U.S. commercial launch of several products, including Integrilin®, Lovenox® and Rilutek®. Mr. Lis served as a member of the Bio Board of Directors for Emerging Companies and is currently an independent Director of Eidos Therapeutics, Inc. and Zai Laboratories, Inc.

What is William Lis' net worth?: The estimated net worth of William Lis is at least $84,240.48 as of October 13th, 2023. Mr. Lis owns 5,352 shares of Zai Lab stock worth more than $84,240 as of April 25th. This net worth evaluation does not reflect any other investments that Mr. Lis may own. Learn More about William Lis' net worth.
How do I contact William Lis?: The corporate mailing address for Mr. Lis and other Zai Lab executives is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. Zai Lab can also be reached via phone at 862161632588 and via email at [email protected]. Learn More on William Lis' contact information.
Has William Lis been buying or selling shares of Zai Lab?: William Lis has not been actively trading shares of Zai Lab over the course of the past ninety days. Most recently, William Lis sold 5,434 shares of the business's stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $38.31, for a transaction totalling $208,176.54. Following the completion of the sale, the director now directly owns 23,330 shares of the company's stock, valued at $893,772.30. Learn More on William Lis' trading history.
Who are Zai Lab's active insiders?: Zai Lab's insider roster includes Kai-Xian Chen (Director), Yajing Chen (CFO), William Cho (CFO), John Diekman (Director), Ying Du (CEO), Frazor Edmondson, III (Insider), Tao Fu (COO), William Lis (Director), Harald Reinhart (Insider), Joshua Smiley (Insider), and Peter Wirth (Director). Learn More on Zai Lab's active insiders.
Are insiders buying or selling shares of Zai Lab?: During the last twelve months, Zai Lab insiders bought shares 2 times. They purchased a total of 9,000 shares worth more than $254,250.00. During the last twelve months, insiders at the sold shares 9 times. They sold a total of 40,476 shares worth more than $940,803.05. The most recent insider tranaction occured on April, 4th when insider Joshua L Smiley sold 1,988 shares worth more than $31,151.96. Insiders at Zai Lab own 5.2% of the company. Learn More about insider trades at Zai Lab.
Information on this page was last updated on 4/4/2024.

William Lis Insider Trading History at Zai Lab

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/3/2023	Sell	5,434	$38.31	$208,176.54	23,330
1/20/2022	Sell	1,926	$53.40	$102,848.40

William Lis Buying and Selling Activity at Zai Lab

Zai Lab Company Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Today's Range

Now: $15.74

$15.05

$15.82

50 Day Range

MA: $17.54

$13.72

$22.49

2 Week Range

Now: $15.74

$13.48

$39.50

Volume

515,424 shs

Average Volume

484,213 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

World’s biggest multibillionaire investor is buying THIS by the ton [picture]

From Stansberry Research | Ad

Click here to find out what to do.